Everand Logo

Welcome to Everand!

  • STAT

    Opinion: What India can teach the U.S. about driving down the cost of health care

    A solution to reducing costs without government intervention and without reducing quality might be found in an unlikely place: India.
    by Vijay Govindarajan and Ravi Ramamurti Jul 10, 2018 4 minutes
    At Narayana Health in Bangalore, India, a typical heart surgery costs thousands of dollars less than it would in the U.S., and the hospital performs 60 percent of pediatric surgeries free or at a discounted price to those who can't pay.

    With the Affordable Care Act under attack and all eyes on Dr. Atul Gawande as he starts this week as CEO of the new Amazon, JPMorgan, and Berkshire Hathaway venture, health care in the United States is more top of mind than ever. Surprisingly, a solution to reducing costs without government intervention and without reducing quality might be found in an unlikely place: India.

    We have visited more than two dozen hospitals and interviewed more than 125 executives across India and the U.S. We learned that some of the most proactive hospitals in the West are adopting the world-class innovations of Indian health care institutions in order to boost quality,

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
    An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
    MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
    Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

    Related Books & Audiobooks